SCHEMBL211981

SCHEMBL211981

Cc1nc(NC(=O)OC(C)(C)C)sc1-c1ccnc(NCc2ccc(C(=O)O)cc2)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PI4KB Q9UBF8 1/20 0.50
CDK2 P24941 3/20 0.49
AURKA O14965 3/20 0.49
CDK7 P50613 3/20 0.49
CDK9 P50750 3/20 0.49
AURKB Q96GD4 3/20 0.49
CDK4 P11802 2/20 0.49
CDK1 P06493 2/20 0.49
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
MAPT P10636 2/20 0.44
ALDH1A1 P00352 1/20 0.44
GAA P10253 1/20 0.44
HPGD P15428 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
PIK3CA P42336 1/20 0.41
LCK P06239 5/20 0.41
VCP P55072 1/20 0.40
FAAH O00519 1/20 0.40
CCNA2 P20248 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27589595 0.81 CDK2 (0.54) CDK2AURKACDK7CDK9AURKB
SCHEMBL210175 0.80 CDK4 (0.54) CDK2AURKACDK7CDK9AURKB
SCHEMBL210412 0.75 CDK2 (0.44) CDK2AURKACDK7CDK9AURKB
SCHEMBL210411 0.74 CDK2 (0.46) CDK2AURKACDK7CDK9AURKB
SCHEMBL8280229 0.74 VCP (0.38) CDK2AURKAPIK3CAVCPCCNA2
SCHEMBL16408476 0.69 VCP (0.59) AURKAMEN1KMT2AALDH1A1HPGD
SCHEMBL1890923 0.69 PIK3CG (0.60) PI4KBCDK2AURKACDK7CDK9
SCHEMBL3589399 0.68 SCD (0.69) ALDH1A1NPSR1LCKRAB9A
SCHEMBL2733463 0.68 HDAC1 (0.59) VCPHDAC1MAPK8CLK2DYRK1A
SCHEMBL209589 0.68 HDAC1 (0.69) VCPHDAC1MAPK8CLK2DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088805-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2012-01-03 US disclosed
US-8088805-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2012-01-03 US disclosed
US-20070213330-A1 Anticancer agents; antiproliferative agents METHYLGENE INC. (CA) 2007-09-13 US disclosed
US-20070213330-A1 Anticancer agents; antiproliferative agents METHYLGENE INC. (CA) 2007-09-13 US disclosed
US-7253204-B2 Antiproliferative agents METHYLGENE INC. (CA) 2007-08-07 US disclosed
US-7253204-B2 Antiproliferative agents METHYLGENE INC. (CA) 2007-08-07 US disclosed
EP-1735319-A1 INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2006-12-27 EP disclosed
US-20050245518-A1 Antiproliferative agents METHYLGENE, INC. 2005-11-03 US disclosed
WO-2005092899-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2005-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213330-A1 Anticancer agents; antiproliferative agents HDAC1, HDAC11, HDAC5 PI4KB 1882/4885CDK2 116/4885AURKA 257/4885
US-20050245518-A1 Antiproliferative agents HDAC1, HDAC11, HDAC5 PI4KB 2548/4885CDK2 72/4885AURKA 496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.